-transparent.png){kind=logo}
Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitotic arrest and death of cancer cells.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Quentin Delacour, and
Olivier Gavet
January 2014,
Current topics in medicinal chemistry,
Quentin Delacour, and
Olivier Gavet
January 2014,
Current topics in medicinal chemistry,
Quentin Delacour, and
Olivier Gavet
May 2010,
Journal of medicinal chemistry,
Quentin Delacour, and
Olivier Gavet
December 2013,
Mini reviews in medicinal chemistry,
Quentin Delacour, and
Olivier Gavet
June 1998,
Current pharmaceutical design,
Quentin Delacour, and
Olivier Gavet
September 1997,
Gan to kagaku ryoho. Cancer & chemotherapy,
Quentin Delacour, and
Olivier Gavet
June 2012,
Hematology/oncology clinics of North America,
Quentin Delacour, and
Olivier Gavet
December 2004,
Bioorganic & medicinal chemistry letters,
Quentin Delacour, and
Olivier Gavet
February 2009,
Bioorganic & medicinal chemistry,
Quentin Delacour, and
Olivier Gavet
June 2014,
Bioorganic & medicinal chemistry letters,
